

**REMARKS**

Claims 1-41 were pending prior to this response. In the Action dated July 21, 2008, the examiner took the position that the claims 1-35 (Group I) and claims 36-41 (Group II) failed to comply with Unity of Invention under PCT Rule 13.1.

Claims 1-35 have been withdrawn. Should these claims not be reinstated during prosecution, in the instance that a common technical feature is shown to exist, applicant reserves the right to file and prosecute divisional applications on the claims of the withdrawn claims.

Applicants herein elect Group II, claims 36-41, for prosecution on the merits. Claim 36 has been amended to incorporate language of claim 1. Applicant has added new method claims 44-76 for further consideration on the merits.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Favorable consideration of the application is hereby requested. If any minor matters exist precluding allowance of this application, the examiner is requested to contact the applicant's representative at the number below.

Respectfully submitted,

/James P. Riek/

Date: July 23, 2008

James P. Riek  
Attorney for Applicant  
Registration No. 39,009

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-8022  
Facsimile: 919-483-7988